"Tetrahydronaphthalenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Partially saturated 1,2,3,4-tetrahydronaphthalene compounds.
| Descriptor ID |
D013764
|
| MeSH Number(s) |
D02.455.426.559.847.638.960 D04.615.638.960
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tetrahydronaphthalenes".
Below are MeSH descriptors whose meaning is more specific than "Tetrahydronaphthalenes".
This graph shows the total number of publications written about "Tetrahydronaphthalenes" by people in this website by year, and whether "Tetrahydronaphthalenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tetrahydronaphthalenes" by people in Profiles.
-
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. Breast Cancer Res. 2024 Jun 07; 26(1):95.
-
Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells. Elife. 2022 05 16; 11.
-
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 05 12; 23(1):54.
-
Clinical Activity of the ?-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). J Clin Oncol. 2017 May 10; 35(14):1561-1569.
-
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015 Sep 25; 5:e350.
-
Comment on "ApoE-directed therapeutics rapidly clear ß-amyloid and reverse deficits in AD mouse models". Science. 2013 May 24; 340(6135):924-f.
-
Recurrent localized primary cutaneous marginal-zone B cell lymphoma. Dermatol Online J. 2011 Oct 15; 17(10):27.
-
Allele-specific down-regulation of RPTOR expression induced by retinoids contributes to climate adaptations. PLoS Genet. 2010 Oct 28; 6(10):e1001178.
-
Potential nonhormonal therapeutics for medical treatment of leiomyomas. Semin Reprod Med. 2004 May; 22(2):121-30.
-
RXR receptor agonist suppression of thyroid function: central effects in the absence of thyroid hormone receptor. Am J Physiol Endocrinol Metab. 2002 Aug; 283(2):E326-31.